The historical rank and industry rank for Zealand Pharma AS's Days Payable or its related term are showing as below:
ZLDPF'
s Days Payable Range Over the Past 10 Years
Min: 62.86 Med: 4097.53 Max: 218666.34
Current: 218666.34
During the past 13 years, Zealand Pharma AS's highest Days Payable was 218666.34. The lowest was 62.86. And the median was 4097.53.
ZLDPF's Days Payable is ranked better than 99.72% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs ZLDPF: 218666.34
Zealand Pharma AS's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Zealand Pharma AS Days Payable Related Terms
Zealand Pharma AS Days Payable Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLDPF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zealand Pharma AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zealand Pharma AS and its competitors. Over the past decade, Zealand Pharma AS's Days Payable has ranged from 62.86 to 218,666.34. According to the industry distribution chart, Zealand Pharma AS ranks #2 out of 707 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Zealand Pharma AS's Days Payable too high?
Zealand Pharma AS's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 62.86 to a high of 218,666.34. Based on the distribution chart, Zealand Pharma AS ranks #2 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #2 out of 707 companies for Days Payable. This places Zealand Pharma AS in the top 0% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Historically, Zealand Pharma AS's own Days Payable has ranged from 62.86 to 218,666.34 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,929.01, compared to a current price of $42.89 — trading 97.8% below its estimated fair value. The current Days Payable is 0.00. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $42.89 is trading 97.8% below its estimated GF Value™ of $1,929.01.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Days Payable: 0.00
GF Value™: $1,929.01 vs. price of $42.89 (97.8% below fair value)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
